Biohaven (NYSE:BHVN) Stock Price Up 9.4% – Still a Buy?

Posted by Brenda Bartman on Sep 17th, 2026

Biohaven Ltd. (NYSE:BHVN – Get Free Report)’s share price was up 9.4% during trading on Thursday . The company traded as high as $13.06 and last traded at $13.1460. 953,347 shares traded hands during trading, a decline of 64% from the average session volume of 2,674,066 shares. The stock had previously closed at $12.02.

Analyst Ratings Changes

Several research firms have recently commented on BHVN. Needham & Company LLC set a $11.00 price objective on shares of Biohaven in a research note on Monday, June 29th. HC Wainwright restated a “neutral” rating and set a $10.00 target price on shares of Biohaven in a research note on Thursday, September 10th. Wall Street Zen raised shares of Biohaven from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Raymond James Financial reiterated a “strong-buy” rating and issued a $30.00 price target on shares of Biohaven in a research note on Wednesday, August 26th. Finally, Royal Bank Of Canada lowered shares of Biohaven from an “outperform” rating to a “sector perform” rating and reduced their price objective for the company from $23.00 to $19.00 in a report on Tuesday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Biohaven currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.69.

View Our Latest Stock Report on Biohaven

Biohaven Stock Performance

The firm has a 50 day moving average of $14.51 and a two-hundred day moving average of $12.13. The stock has a market cap of $2.01 billion, a PE ratio of -2.87 and a beta of 1.28. The company has a debt-to-equity ratio of 21.23, a current ratio of 4.73 and a quick ratio of 4.73.

Biohaven (NYSE:BHVN – Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.15). Research analysts predict that Biohaven Ltd. will post -3.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Biohaven

Several hedge funds and other institutional investors have recently bought and sold shares of BHVN. BlackRock Inc. acquired a new position in Biohaven in the second quarter valued at $196,574,000. Janus Henderson Group PLC lifted its holdings in shares of Biohaven by 1,145.9% in the 1st quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company’s stock valued at $148,214,000 after purchasing an additional 16,127,247 shares during the last quarter. Jupiter Topco LLC purchased a new stake in shares of Biohaven in the 2nd quarter valued at about $127,852,000. BNP Paribas Financial Markets boosted its position in shares of Biohaven by 148.2% in the 4th quarter. BNP Paribas Financial Markets now owns 2,093,816 shares of the company’s stock valued at $23,639,000 after purchasing an additional 1,250,252 shares during the period. Finally, Bank of America Corp DE acquired a new stake in shares of Biohaven in the 2nd quarter valued at about $21,990,000. 88.78% of the stock is currently owned by institutional investors and hedge funds.

Biohaven Company Profile

(Get Free Report)

Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and immunological disorders. The company’s research programs use a range of approaches, including small-molecule medicines, biologics and other targeted therapies, with the goal of addressing diseases that have limited or inadequate treatment options.

Biohaven’s pipeline has included investigational treatments for conditions such as epilepsy, obsessive-compulsive disorder, neurodegenerative diseases, neuroinflammatory disorders and immune-mediated diseases.